We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Urology

Journal Scan / Research · October 03, 2022

Neoadjuvant Degarelix With or Without Apalutamide Before Radical Prostatectomy for High-Risk Prostate Cancer

European Urology

 

Additional Info

Disclosure statements are available on the authors' profiles:

European Urology
ARNEO: A Randomized Phase II Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-risk Prostate Cancer
Eur Urol 2022 Sep 24;[EPub Ahead of Print], G Devos, L Tosco, M Baldewijns, et al

Advanced Prostate Cancer Center of Excellence

Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.


Further Reading